• Cellvizio®
    • Overview
    • Education
    • Economics
    • Indications
      • Gastroenterology
        • Barrett’s Esophagus
        • Pancreatic Cysts
        • Gastric Disease
        • Inflammatory Bowel Diseases
        • Irritable Bowel Syndrome – Food Intolerance
        • Bilio-Pancreatic Strictures
        • Colorectal Lesions
      • Pulmonology
        • Lung Nodules
        • Lung Transplant
      • Urology
  • Investors
    • Overview
    • Events and Presentations
    • Financials
    • Governance
  • About Us
    • Our Story
    • Team
      • Board of Directors
      • Leadership Team
    • Join Us
    • Commercial network
  • Newsroom
    • News
    • Events
    • Press Coverage
  • INT
    • US
    • FR
Mauna Kea Technologies publishes Q1 2022 sales and its 2021 financial results

Mauna Kea Technologies publishes Q1 2022 sales and its 2021 financial results

by Zina | Apr 21, 2022 | News

Following its 2021 restructuring, Company experiences stable U.S sales growth, including improved gross margin and anticipated reductions in operating losses Mauna Kea Technologies today announced financial results (unaudited) for the year ended December 31,...
Mauna Kea Technologies publishes Q1 2022 sales and its 2021 financial results

Mauna Kea Technologies Announces First of Its Kind U.S. FDA 510(k) Clearance for Use of Cellvizio in a New Category of Molecular Imaging-guided Endoscopic, Laparoscopic, Needle-Based Procedures

by Zina | Apr 12, 2022 | News

Completion of a Major Regulatory Milestone for Molecular Imaging and Precision Medicine as Part of Ongoing Collaboration Mauna Kea Technologies today announced a new U.S. FDA 510(k) clearance (K220477) for the use of the Cellvizio 100 Series platform with a...
Mauna Kea Technologies publishes Q1 2022 sales and its 2021 financial results

Mauna Kea Technologies to Present at 32nd Annual Oppenheimer Healthcare Conference on March 17, 2022

by Zina | Mar 10, 2022 | Events

Mauna Kea Technologies today announced that the Company is participating in the 32nd Annual Oppenheimer Healthcare investor conference, to be held virtually from March 15-17, 2022. Sacha Loiseau, Ph.D., Chairman and Founder, is scheduled to present on March 17,...
Mauna Kea Technologies publishes Q1 2022 sales and its 2021 financial results

On Target Laboratories and Mauna Kea Technologies Announce a Novel Clinical Research and Product Development Collaboration

by Zina | Mar 8, 2022 | News

The collaboration will explore and establish the value of molecular image-guided procedures for the identification and diagnosis of pulmonary cancers during interventional bronchoscopy, leveraging two complementary technologies On Target Laboratories, Inc. and...
The Role of in vivo Cellular Imaging in Managing Lung Disease

The Role of in vivo Cellular Imaging in Managing Lung Disease

by Zina | Mar 4, 2022 | Press Coverage

Although the technology is relatively new, there is a growing body of research that demonstrates the efficacy of confocal laser endomicroscopy (CLE), illustrating its broad application and future potential.Read the complete article
« Older Entries
Next Entries »

Articles récents

  • Mauna Kea Technologies announces results of its Combined General Meeting of June 5, 2025 
  • Mauna Kea Technologies Announces Major AI Breakthrough with Cellvizio in Pancreatic Cystic Lesion Risk Stratification 
  • Mauna Kea Technologies Provides Update on Safeguard Proceedings, Strategic Discussions and Operational Progress 
  • Mauna Kea Technologies announces the availability of preparatory documents for the Combined General Meeting of June 5, 2025 and the instructions for participation 
  • Mauna Kea Technologies Announces Largest Annual Pancreatic Cyst Consortium at Digestive Disease Week® 2025 

Commentaires récents

No comments to show.

Company Info

About Us

Join Us

Contact Us

Legal

Legal notice

Privacy policy

Our websites

Cellvizio.net

cell-tolerance.com

Diagnosingbarretts.org

Diagnosingpancreaticcysts.org

Follow us

  • Follow
  • Follow
  • Follow
  • Follow
Manage Consent
To provide the best experiences, we use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us to process data such as browsing behavior or unique IDs on this site. Not consenting or withdrawing consent, may adversely affect certain features and functions.
Functional Always active
The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.
Preferences
The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
Statistics
The technical storage or access that is used exclusively for statistical purposes. The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.
Marketing
The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.
Manage options Manage services Manage {vendor_count} vendors Read more about these purposes
View preferences
{title} {title} {title}